Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 287

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Targeting CD73 in the tumor microenvironment with MEDI9447

Open access
Hay, Carl M., Sult, Erin, Huang, Qihui, Mulgrew, Kathy, Fuhrmann, Stacy R., McGlinchey, Kelly A., Hammond, Scott A., Rothstein, Raymond, Rios-Doria, Jonathan, Poon, Edmund, Holoweckyj, Nick, Durham, Nicholas M., Leow, Ching Ching, Diedrich, Gundo, Damschroder, Melissa, Herbst, Ronald, Hollingsworth, Robert E., Sachsenmeier, Kris F.·2016·OncoImmunology

Abstract

MEDI9447 is a human monoclonal antibody that is specific for the ectoenzyme CD73 and currently undergoing Phase I clinical trials. Here we show that MEDI9447 is a potent inhibitor of CD73 ectonucleotidase activity, with wide ranging immune regulatory consequences. MEDI9447 results in relief from adenosine monophosphate (AMP)-mediated lymphocyte suppression in vitro and inhibition of mouse syngeneic tumor growth in vivo. In contrast with other cancer immunotherapy agents such as checkpoint inhibitors or T-cell agonists, MEDI9447 drives changes in both myeloid and lymphoid infiltrating leukocyte populations within the tumor microenvironment of mouse models. Changes include significant alterations in a number of tumor micro-environmental subpopulations including increases in CD8(+) effector cells and activated macrophages. Furthermore, these changes correlate directly with responder and non-responder subpopulations within animal studies using syngeneic tumors. Combination data showing additive activity between MEDI9447 and anti-PD-1 antibodies using human cells in vitro and mouse tumor models further demonstrate the potential value of relieving adenosine-mediated immunosuppression. Based on these data, a Phase I study to test the safety, tolerability, and clinical activity of MEDI9447 in cancer patients was initiated (NCT02503774).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2016.1208875

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 287

Metadata

Authors
Hay, C. M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S. R., McGlinchey, K. A., Hammond, S. A., Rothstein, R., Rios-Doria, J., Poon, E., Holoweckyj, N., Durham, N. M., Leow, C. C., Diedrich, G., Damschroder, M., Herbst, R., Hollingsworth, R. E., & Sachsenmeier, K. F.
Venue
OncoImmunology
Published
2016-07-11
Volume
5
Issue
8
Pages
e1208875
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2474535137
Cited by
287
References
36
FWCI
19.65
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting CD73 in the tumor microenvironment with MEDI9447. https://app.cochat.ai/papers/10.1080/2162402x.2016.1208875
The paper
Hay, C. M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S. R., McGlinchey, K. A., Hammond, S. A., Rothstein, R., Rios-Doria, J., Poon, E., Holoweckyj, N., Durham, N. M., Leow, C. C., Diedrich, G., Damschroder, M., Herbst, R., Hollingsworth, R. E., & Sachsenmeier, K. F. (2016). Targeting CD73 in the tumor microenvironment with MEDI9447. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1208875

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.